home / stock / osir / osir news

OSIR News and Press, Osiris Therapeutics Inc. From 10/30/18

Stock Information
Company Name: Osiris Therapeutics Inc.
Stock Symbol: OSIR
Market: NASDAQ
Menu
OSIR OSIR Quote OSIR Short OSIR News OSIR Articles OSIR Message Board
Get OSIR Alerts

News, Short Squeeze, Breakout and More Instantly...
OSIR - Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada

COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium o...
OSIR - Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage

COLUMBIA, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Propert...

OSIR - Osiris Therapeutics, Inc. Announces GrafixPL PRIME(TM) Launches October 1, 2018

COLUMBIA, Md., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane th...

OSIR - Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi

COLUMBIA, Md., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc.  (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled &#x...
OSIR - Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018

COLUMBIA, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that The Nasdaq Stock Market LLC has approved its applica...

OSIR - Osiris Therapeutics: Actions Speak Louder Than Words

Picture source: Osiris Therapeutics Osiris Therapeutics (OTC: OSIR ) addresses unmet medical needs in the area of wound care, orthopedics, and sports medicine utilizing regenerative medicine. The company doesn't talk much and no analyst currently covers the company, but it is quietly adv...

OSIR - Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

Stocks in News: TORC, RHHBY ResTORbio's RTB101 shows treatment benefit in mid-stage study; shares up 9% Discussion : ResTORbio ( TORC ) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infecti...
OSIR - Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME(TM) in the Treatment of Chronic Venous Leg Ulcers

COLUMBIA, Md., July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation of its “Multicenter, Prospective, Rand...

OSIR - Osiris Announces Implementation of Prestige Lyotechnology? Preservation Method Allowing Ambient Storage of Living Tissues

COLUMBIA, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today the implementation of Prestige Lyotechnology for manuf...

OSIR - Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting

COLUMBIA, Md., April 25, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “...
Previous 10 Next 10